Effects of zoledronic acid on bone metabolism disturbance in the femur of type 1 diabetic rat models

doi:10.3969/j.issn.2095-4344.2015.40.002

Abstract

Abstract:

BACKGROUND: Osteoporosis caused by diabetes mellitus as common secondary osteoporosis has been paid more and more attention recently. Zoledronic acid serves as a novel drug for osteoporosis, and its effect on osteoblasts in vivo remains unclear.

OBJECTIVE: To investigate the changes of the expression of bone morphogenetic protein 2 and Noggin in the femur of type 1 diabetes mellitus rats and the effect of zoledronic acid on them.

METHODS: Models of type 1 diabetes mellitus were established by intraperitoneal injection of streptozotocin in 130 Wistar rats. 3 days later, rats with blood sugar > 16.7 mmol/L for three consecutive times were considered as successful models, 120 in total. These models were randomly divided into model, prevention and treatment groups. Rats in the prevention and treatment groups were intravenously administered zoledronic acid (0.1 mg/kg) on the day of modeling and 2 weeks after model establishment. An additional 40 rats were injected with citrate buffer solution as control group.

RESULTS AND CONCLUSION: Compared with the control group, femur bone mineral density, serum alkaline phosphatase levels, and femur bone morphogenetic protein 2 mRNA expression levels were significantly lower in the model group (P < 0.05), but Noggin mRNA expression significantly increased (P < 0.05). Compared with the model group, bone mineral density and bone morphogenetic protein 2 mRNA expression levels were significantly higher in the prevention and treatment groups (P < 0.05), but Noggin mRNA expression significantly lower (P < 0.05), and serum alkaline phosphatase levels gradually restored. These results indicated that the bone metabolic disturbance occurs in early stage in rats with type 1 diabetes mellitus. Zoledronic acid can promote bone formation, increase bone density, and improve bone metabolism.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

Key words: Diabetes Mellitus, Type 1, Osteoporosis, Bone Diseases, Metabolic, Bone Density

CLC Number:

R318

Cao Lu-ning, Cui Min, Yu Ling-zhi, Zhang Na, Zhao Xu. Effects of zoledronic acid on bone metabolism disturbance in the femur of type 1 diabetic rat models[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(40): 6402-6407.

Figures/Tables 3

References

[1] Janghorbani M, Hu FB, Willett WC, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care. 2007;30(7):1730-1735.
[2] Neumann T, Sämann A, Lodes S, et al. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet Med. 2011;28(7):872-875.
[3] Cosman F. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract. 2009;15(5):483-493.
[4] Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am. 2012;41(3): 487-506.
[5] Huang S, Lin H, Zhu X, et al. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis. Endokrynol Pol. 2014;65(2): 96-104.
[6] Terpos E, Dimopoulos MA, Berenson J. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Crit Rev Oncol Hematol. 2011;77 Suppl 1:S13-23.
[7] Kamiya N. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol. 2012; 5(2):153-163.
[8] Liu EY, Wactawski-Wende J, Donahue RP, et al. Does low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care. 2003;26(8):2365-2369.
[9] Heap J, Murray MA, Miller SC, et al. Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. J Pediatr. 2004; 144(1): 56-62.
[10] Ebeling PR, Burr DB. Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible? J Bone Miner Res. 2008;23(1):2-5.
[11] Debiais F. Biomarkers of bone remodelling. Bull Cancer. 2013;100(11):1093-1100.
[12] Bowe JE, Franklin ZJ, Hauge-Evans AC, et al. Metabolic phenotyping guidelines: assessing glucose homeostasis in rodent models. J Endocrinol. 2014;222(3):G13-25.
[13] Cui M, Yu L Z, Zhang N, et al. Zoledronic acid improves bone quality in the streptozotocin-induced diabetes rat through upregulating the expression of osteogenic genes. Osteoporos Int. 2013;24:S635-S636.
[14] Yu LZ, Cui M, Sun J. Bone quality changes in the streptozotocin-induced diabetes rat and the effect of zolendronic acid through upregulating the expreesion of the osteogenetic genes. J Bone Miner Res. 2014;29(9):s405.
[15] Silva MJ, Touhey DC. Bone formation after damaging in vivo fatigue loading results in recovery of whole-bone monotonic strength and increased fatigue life. J Orthop Res. 2007;25(2): 252-261.
[16] 孙明霞,韩琳,王国明,等.1型糖尿病病人骨密度的变化及其影响因素[J].青岛大学医学院学报,2014,50(4):432-434.
[17] Massé PG, Pacifique MB, Tranchant CC, et al. Bone metabolic abnormalities associated with well-controlled type 1 diabetes (IDDM) in young adult women: a disease complication often ignored or neglected. J Am Coll Nutr. 2010;29(4):419-429.
[18] Mace PD, Cutfield JF, Cutfield SM. High resolution structures of the bone morphogenetic protein type II receptor in two crystal forms: implications for ligand binding. Biochem Biophys Res Commun. 2006;351(4):831-838.
[19] Cao X, Chen D. The BMP signaling and in vivo bone formation. Gene. 2005;357(1):1-8.
[20] Kanakaris NK, Petsatodis G, Tagil M, et al. Is there a role for bone morphogenetic proteins in osteoporotic fractures? Injury. 2009;40 Suppl 3:S21-26.
[21] Seeherman HJ, Li XJ, Smith E, et al. Intraosseous injection of rhBMP-2/calcium phosphate matrix improves bone structure and strength in the proximal aspect of the femur in chronic ovariectomized nonhuman primates. J Bone Joint Surg Am. 2013;95(1):36-47.
[22] Wang Y, Shan J, Yang W, et al. High mobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins. Inflammation. 2013;36(6):1592-1604.
[23] Zehentner BK, Haussmann A, Burtscher H. The bone morphogenetic protein antagonist Noggin is regulated by Sox9 during endochondral differentiation. Dev Growth Differ. 2002;44(1):1-9.
[24] Moffett SP, Dillon KA, Yerges LM, et al. Identification and association analysis of single nucleotide polymorphisms in the human noggin (NOG) gene and osteoporosis phenotypes. Bone. 2009;44(5):999-1002.
[25] Wu XB, Li Y, Schneider A, et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest. 2003;112(6):924-934.
[26] Baud'huin M, Solban N, Cornwall-Brady M, et al. A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. Proc Natl Acad Sci U S A. 2012; 109(30):12207-12212.
[27] Debeer P, Huysmans C, Van de Ven WJ, et al. Carpal and tarsal synostoses and transverse reduction defects of the toes in two brothers heterozygous for a double de novo NOGGIN mutation. Am J Med Genet A. 2005;134(3):318-320.
[28] Debeer P, Huysmans C, Van de Ven WJ, et al. Carpal and tarsal synostoses and transverse reduction defects of the toes in two brothers heterozygous for a double de novo NOGGIN mutation. Am J Med Genet A. 2005;134(3):318-320.